Latest Breaking News On - Breast oncology - Page 7 : comparemela.com

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

William gradisharRena callahanMabel mardonesGregory vidalPeer exchangeOral serdMetastatic breast cancerTherapeutic advancesPanel discussionHer positiveHer2 negativeSelective estrogen receptor degraderEndocrine therapyTargeted therapyTreatment developmentsMedical oncology

Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Breast cancerClinical guidelinesOral serdMetastatic breast cancerTherapeutic advancesPanel discussionHer positiveHer2 negativeSelective estrogen receptor degraderEndocrine therapyTargeted therapyTreatment developmentsMedical oncologyBreast oncologyFda labelNccn guidelines

Jaguar Health, Inc : Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea

Jaguar Health, Inc : Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Nordrhein westfalenSan antonioUnited statesStefan klotterMichael guyLisa conteSandram swainEric roelandPaula pohlmannMagdalena biosciencesPabloc okhuysenJaguar entheogen therapeutics initiativeJaguar animal healthMultinational association of supportive care in cancerGeorgetown universityBreast cancer research

Dog Study Published in PLOS ONE Shows Statistically Significant Results

Dog Study Published in PLOS ONE Shows Statistically Significant Results .

Michael guyLisa conteNews networkNapo pharmaceuticalsPuma biotechnology incGenentech incBreast cancer researchJaguar health incPuma biotechnologyJaguar healthNeratinib associated diarrheaPatients withEarly stage breast cancerClinical breast cancerWinterhof family professorBreast oncology

Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD) | Region

This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention

San antonioUnited statesPaula pohlmannMichael guyMagdalena biosciencesEric roelandLisa conteSandram swainPabloc okhuysenLombardi comprehensive cancer centerJaguar healthAmerican cancer societyJaguar animal healthBreast cancer researchGenentech incJaguar health inc